en · de · es · pt
assay-notes.peptides9002.com › Topic › Background And Clinical Development — Reference Sheet

Background And Clinical Development — Reference Sheet

By Editorial Desk · published 2025-09-10 · last reviewed 2025-10-23 · Topic

冻干粉 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2025-10-23. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Clinical Development

Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.

A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.

Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.

Mechanism And Measurement Approaches

Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.

Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.

Tesamorelin at a glance

PropertyValueNotes
Molecular weightApproximately 5,136 DaBased on the 44-amino-acid peptide backbone and N-terminal modification.
AppearanceWhite to off-white lyophilized powderUsually supplied in single-use vials for reconstitution.
SolubilityFreely soluble in water; slightly soluble in some organic solventsPeptide nature supports aqueous reconstitution.
Typical storage2–8 °C, protected from lightRefrigeration reduces degradation; avoid freezing unless specified.
Common analytical methodReverse-phase high-performance liquid chromatographyUsed for identity, purity, and quantification.
SynonymsTesamorelin, TH9507, GHRH(1-44) analogGeneric descriptors; avoid proprietary names.

Background And Regulatory Development

Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.

Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.

Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.

Related pages on this site

检测方法、储存与处理

冻干粉末一般在 -20°C 或更低温度、干燥避光条件下保存,可维持较长时间的稳定。复溶后稳定性明显下降,溶液中的肽链易发生水解、氧化与聚集,通常需冷藏并在短期内用完。反复冻融会加速聚集与降解,建议分装后单次使用。缓冲体系的 pH 与离子强度同样影响聚集速率,需要按具体实验条件验证。

研究用与临床用材料的标准并不相同。质量控制通常覆盖纯度、残留溶剂、反离子含量、微生物限度与内毒素水平,各项均有对应检测方法。随货文件应包含批号、检测项目、方法与结果,使数据可以追溯。核验时应关注纯度是否按主峰面积计算、杂质是否已定性、方法是否经过验证,这些信息决定结果能否被外部重复。

Identity and Development Background

Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Analytical Monitoring Approaches

Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.

Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.

Background from the literature

Pterygoplichthyini is a tribe of catfishes (order Siluriformes) of the family Loricariidae. It includes two genera, Pterygoplichthys and the currently undescribed genus referred to as the Hemiancistrus annectens group, This group was earlier misspelled as Pterygoplichthini. Pterygoplichthyines are known from nearly the entire range of loricariids except for the Guyanas and coastal streams in southeastern Brazil. although later work by the same authority, and his co-authors, placed this group among the genus Hypostomus. Pterygoplichthyini is sister to the tribe Ancistrini, which shares the derived presence of an evertible patch of plates on the cheek. Pterygoplichthys and the H. annectens group differ most obviously in the number of dorsal fin rays (7 in the H. annectens group and 9+ in Pterygoplichthys). The two genera are supported as sisters by only one derived characteristic: a modified stomach that is attached to the abdominal wall by a net of connective tissue. This modified stomach allows these fish to breathe air. The stomach is vascularized. A white net of connective tissue surrounds the organ, leaving a circular area in the middle of the stomach free; this connective tissue firmly holds the stomach to the body wall and is better developed in adults. It may also function as a hydrostatic organ, allowing the fish to remain buoyant midwater.

=== Discovery of GLP-2 actions leading to Short Bowel Syndrome treatments === In 1996, Drucker also discovered the first biological actions for GLP-2, demonstrating that it augmented crypt cell proliferation and expansion of the mucosal epithelium in the small bowel of mice and rats. He subsequently identified and characterized a DPP-4-resistant molecule, teduglutide, that was ultimately developed and approved for the treatment of short bowel syndrome in adults and children, a disorder in which fluids are poorly absorbed after resection of the small intestine.

lethal mutation Any mutation that results in the premature death of the organism carrying it. Recessive lethal mutations are fatal only to homozygotes, whereas dominant lethals are fatal even in heterozygotes.

Sources: en.wikipedia.org

Reference notes

== Interactions == Proteases such as trypsin and clostridiopeptidase, which are contained in ointments used for the removal of dead skin on wounds, can be inhibited by silver ions if applied simultaneously. When silver sulfadiazine is absorbed in significant amounts, it can increase effects and side effects of some drugs such as vitamin K antagonists.

10 December – The Metropolitan Police confirms that Deveca Rose, a 29-year-old mother, whose four children died in a South London house fire in December 2021, has been charged with manslaughter. Rose also faces charges of child abandonment. The skull of a pliosaur has been excavated from the cliffs of Dorset's Jurassic Coast. McDonald's says it has "permanently removed" a "third party security guard" who was filmed the previous day kicking a homeless man's possessions out of the way while mopping the floor outside the food outlet's premises in Victoria Street, London. The footage gained public attention after it was posted on social media. 11 December – Following a trial at the Old Bailey, Ashana Studholme, Lisa Richardson and Shaun Pendlebury are convicted of the September 2022 murder of Shakira Spencer, a west London mother-of-two, who was tortured, starved and beaten to death by the trio. The Association of School and College Leaders (ASCL) and National Association of Head Teachers (NAHT) issue a joint statement calling for the immediate pause of Ofsted inspections following the outcome of the inquest into the death of Ruth Perry. 12 December – Nottingham City Council outlines a programme of cost savings, including the loss of 550 jobs, as it seeks to deal with a £50m deficit. At a meeting with MPs, Sir Adrian Montague, chairman of Thames Water, says that the company cannot afford to repay a £190m loan which is due in April 2024.

1936: Danish seismologist and geophysicist Inge Lehmann discovered that the Earth has a solid inner core distinct from its molten outer core. 1937: Canadian forensic pathologist Frances Gertrude McGill assisted the Royal Canadian Mounted Police in establishing their first forensic detection laboratory. 1937: Suzanne Comhaire-Sylvain became the first female Haitian anthropologist and the first Haitian person to complete a PhD, receiving her doctoral degree from the University of Paris. 1937: Marietta Blau and her student Hertha Wambacher, both Austrian physicists, received the Lieben Prize of the Austrian Academy of Sciences for their work on cosmic ray observations using the technique of nuclear emulsions. 1938: Nigerian physician Elizabeth Abimbola Awoliyi became the first woman to be licensed to practise medicine in Nigeria after graduating from Trinity College Dublin and the first West African female medical officer with a license of the Royal Surgeon (Dublin). 1938: Canadian geologist Alice Wilson became the first woman appointed as Fellow to the Royal Society of Canada. 1938: South African naturalist Marjorie Courtenay-Latimer discovered a living coelacanth fish caught near the Chalumna river. The species had been believed to be extinct for over 60 million years. It was named latimeria chalumnae in her honour.

Sources: en.wikipedia.org

Reference notes

A hypnotic (from Greek Hypnos, sleep), also known as a somnifacient or soporific, and commonly known as sleeping pills, are a class of psychoactive drugs whose primary function is to induce sleep and to treat insomnia (sleeplessness). Some hypnotics are also used to treat narcolepsy and hypersomnia by improving sleep at night and thereby reducing daytime sleepiness. Certain hypnotics can be used to treat non-restorative sleep and associated symptoms in conditions like fibromyalgia as well. This group of drugs is related to sedatives. Whereas the term sedative describes drugs that serve to calm or relieve anxiety, the term hypnotic generally describes drugs whose main purpose is to initiate, sustain, or lengthen sleep. Because these two functions frequently overlap, and because drugs in this class generally produce dose-dependent effects (ranging from anxiolysis to loss of consciousness), they are often referred to collectively as sedative–hypnotic drugs. Hypnotic drugs are regularly prescribed for insomnia and other sleep disorders, with over 95% of insomnia patients being prescribed hypnotics in some countries. Many hypnotic drugs are habit-forming and—due to many factors known to disturb the human sleep pattern—a physician may instead recommend changes in the environment before and during sleep, better sleep hygiene, the avoidance of caffeine and alcohol or other stimulating substances, or behavioral interventions such as cognitive behavioral therapy for insomnia (CBT-I), before prescribing medication for sleep.

The underlined nucleotides indicate the translation start codon, coding for Methionine. upper-case letters indicate highly conserved bases, i.e. the 'AUGG' sequence is constant or rarely, if ever, changes. 'R' indicates that a purine (adenine or guanine) is always observed at this position (with adenine being more frequent according to Kozak) a lower-case letter denotes the most common base at a position where the base can nevertheless vary the sequence in parentheses (gcc) is of uncertain significance. The AUG is the initiation codon encoding a methionine amino acid at the N-terminus of the protein. (Rarely, GUG is used as an initiation codon, but methionine is still the first amino acid as it is the met-tRNA in the initiation complex that binds to the mRNA). Variation within the Kozak sequence alters the "strength" thereof. Kozak sequence strength refers to the favorability of initiation, affecting how much protein is synthesized from a given mRNA. The A nucleotide of the "AUG" is delineated as +1 in mRNA sequences with the preceding base being labeled as −1, i.e. there is no 0 position. For a 'strong' consensus, the nucleotides at positions +4 (i.e. G in the consensus) and −3 (i.e. either A or G in the consensus) relative to the +1 nucleotide must both match the consensus. An 'adequate' consensus has only 1 of these sites, while a 'weak' consensus has neither. The cc at −1 and −2 are not as conserved, but contribute to the overall strength. There is also evidence that a G in the -6 position is important in the initiation of translation.

=== Autologous fat transplant === This variation of the procedure uses the patient's own fat cells, and therefore is non-allergenic and non-immunogenic. The fat cells are taken from the abdominal wall by suction. Then they are purified and put into a saline solution before injection. When used in other fields such as urology or facial surgery, autologous fat transplants have very rarely been reported to cause fat embolism and stroke. This material is also subject to rapid digestion and migration.

Since the release of nonbenzodiazepines, also known as z-drugs, in 1992 in response to safety concerns, individuals with insomnia and other sleep disorders have increasingly been prescribed nonbenzodiazepines (2.3% in 1993 to 13.7% of Americans in 2010), and less often prescribed benzodiazepines (23.5% in 1993 to 10.8% in 2010). It is not clear as to whether the new non benzodiazepine hypnotics (Z-drugs) are better than the short-acting benzodiazepines. The efficacy of these two groups of medications is similar. According to the US Agency for Healthcare Research and Quality, indirect comparison indicates that side-effects from benzodiazepines may be about twice as frequent as from nonbenzodiazepines. Some experts suggest using nonbenzodiazepines preferentially as a first-line long-term treatment of insomnia. However, the UK National Institute for Health and Clinical Excellence did not find any convincing evidence in favor of Z-drugs. NICE review pointed out that short-acting Z-drugs were inappropriately compared in clinical trials with long-acting benzodiazepines. There have been no trials comparing short-acting Z-drugs with appropriate doses of short-acting benzodiazepines. Based on this, NICE recommended choosing the hypnotic based on cost and the patient's preference. Older adults should not use benzodiazepines to treat insomnia unless other treatments have failed.

Sources: en.wikipedia.org

Frequently asked questions

What is tesamorelin?

It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.

Which patient group was studied in pivotal trials?

Pivotal trials enrolled adults with HIV and excess visceral abdominal fat, often in the context of antiretroviral therapy. Participants were assessed mainly by computed tomography for visceral adipose tissue. The approved indication remains specific to that population.

What remains uncertain about its long-term effects?

Long-term effects on cardiovascular events, mortality, and sustained fat distribution are not well established. Most trials measured changes over months rather than years. Open questions also include whether benefits persist after treatment stops.

What receptor does tesamorelin act on?

It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.

Network